Robert Roskoski

List of Publications by Year
in descending order

56 papers	13,245 citations	61945 43 h-index	149623 56 g-index
58 all docs	58 docs citations	58 times ranked	18030 citing authors

#	Article	IF	Citations
1	ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacological Research, 2012, 66, 105-143.	3.1	1,246
2	The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 2014, 79, 34-74.	3.1	1,028
3	[1] Assays of protein kinase. Methods in Enzymology, 1983, 99, 3-6.	0.4	803
4	Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacological Research, 2016, 103, 26-48.	3.1	570
5	Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical Reviews in Oncology/Hematology, 2007, 62, 179-213.	2.0	515
6	Src kinase regulation by phosphorylation and dephosphorylation. Biochemical and Biophysical Research Communications, 2005, 331, 1-14.	1.0	501
7	Src proteinâ€“tyrosine kinase structure and regulation. Biochemical and Biophysical Research Communications, 2004, 324, 1155-1164.	1.0	471
8	Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacological Research, 2015, 94, 9-25.	3.1	416
9	Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacological Research, 2020, 152, 104609.	3.1	415
10	Adenosine cyclic 3',5'-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. Biochemistry, 1982, 21, 5794-5799.	1.2	403
11	A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacological Research, 2015, 100, 1-23.	3.1	391
12	Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research, 2019, 144, 19-50.	3.1	377
13	Rapid protein kinase assay using phosphocellulose-paper absorption. Analytical Biochemistry, 1975, 66, 253-258.	1.1	360
14	The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochemical and Biophysical Research Communications, 2004, 319, 1-11.	1.0	349
15	Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochemical and Biophysical Research Communications, 2007, 356, 323-328.	1.0	342
16	Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacological Research, 2019, 139, 395-411.	3.1	315
17	Structure and regulation of Kit protein-tyrosine kinaseâ€”The stem cell factor receptor. Biochemical and Biophysical Research Communications, 2005, 338, 1307-1315.	1.0	299
18	RAF protein-serine/threonine kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 2010, 399, 313-317.	1.0	296

#	Article	IF	Citations
19	Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacological Research, 2016, 111, 784-803.	3.1	279
20	Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacological Research, 2019, 139, 471-488.	3.1	270
21	Signaling by Kit protein-tyrosine kinaseâ€"The stem cell factor receptor. Biochemical and Biophysical Research Communications, 2005, 337, 1-13.	1.0	258
22	Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacological Research, 2021, 165, 105463.	3.1	242
23	Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition. Pharmacological Research, 2013, 68, 68-94.	3.1	238
24	VEGF receptor proteinâ€"tyrosine kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 2008, 375, 287-291.	1.0	228
25	MEK1/2 dual-specificity protein kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 2012, 417, 5-10.	1.0	213
26	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacological Research, 2019, 142, 151-168.	3.1	202
27	Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacological Research, 2017, 120, 116-132.	3.1	184
28	Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacological Research, 2016, 107, 249-275.	3.1	179
29	ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacological Research, 2014, 87, 42-59.	3.1	161
30	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research, 2018, 135, 239-258.	3.1	154
31	Protein prenylation: a pivotal posttranslational process. Biochemical and Biophysical Research Communications, 2003, 303, 1-7.	1.0	141
32	Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacological Research, 2022, 175, 106037.	3.1	136
33	The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharmacological Research, 2018, 129, 65-83.	3.1	117
34	STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochemical and Biophysical Research Communications, 2003, 309, 709-717.	1.0	101
35	Complex molecular regulation of tyrosine hydroxylase. Journal of Neural Transmission, 2014, 121, 1451-1481.	1.4	97
36	Guidelines for preparing color figures for everyone including the colorblind. Pharmacological Research, 2017, 119, 240-241.	3.1	94

#	Article	IF	Citations
37	ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacological Research, 2017, 121, 202-212.	3.1	93
38	Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacological Research, 2018, 128, 1-17.	3.1	91
39	The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacological Research, 2020, 151, 104567.	3.1	88
40	Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacological Research, 2017, 117, 343-356.	3.1	87
41	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacological Research, 2017, 117, 20-31.	3.1	78
42	Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacological Research, 2016, 113, 395-408.	3.1	70
43	The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacological Research, 2018, 133, 35-52.	3.1	66
44	Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). Pharmacological Research, 2021, 165, 105422.	3.1	46
45	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacological Research, 2021, 168, 105579.	3.1	39
46	Role of the Carboxyterminal Residue in Peptide Binding to Protein Farnesyltransferase and Protein Geranylgeranyltransferase. Archives of Biochemistry and Biophysics, 1998, 356, 167-176.	1.4	35
47	The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. Expert Opinion on Drug Discovery, 2013, 8, 1165-1179.	2.5	32
48	Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Pharmacological Research, 2022, 178, 106156.	3.1	30
49	The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. Pharmacological Research, 2020, 155, 104725.	3.1	21
50	NIH funding trends to US medical schools from 2009 to 2018. PLoS ONE, 2020, 15, e0233367.	1.1	17
51	Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Pharmacological Research, 2021, 172, 105806.	3.1	17
52	Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes. Pharmacological Research, 2021, 169, 105660.	3.1	16
53	Michaelis-Menten Kineticsâ˜†. , 2015, , .		13
54	A Primer on BRIMR. American Journal of Pathology, 2022, 192, 392-394.	1.9	7

#	Article	IF	Citations
55	Fritz Lipmann (1899â€“1986): an appreciation. Trends in Biochemical Sciences, 1987, 12, 136-138.	3.7	3
56	Writing it right for Pharmacological Research. Pharmacological Research, 2021, 170, 105733.	3.1	0